http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105906501-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C49-835 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C45-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2016-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105906501-B |
| titleOfInvention | Compound and preparation method thereof, application |
| abstract | The present invention relates to chemical fields, in particular to compound and preparation method thereof, application.Compound provided by the invention has stronger alpha-glucosaccharase enzyme inhibition activity, can be used in preparing hypoglycemic drug.Double chalcones alpha-glucosidase restrainers can be obtained using two-step reaction in the present invention, and reaction step is simple.External pharmacological evaluation shows that compound provided by the invention has certain inhibiting effect to alpha-glucosidase.Simultaneously, cell-based assay discovery compound does not significantly affect the glucose uptake activity of HepG-2 cell exogenous, and compound ccy-13 (1 μM) obviously (P < 0.05) can reduce glucose inside cells content (~40%), close to positive controls PG (5 μM), show that compound ccy-13 has stronger alpha-glucosaccharase enzyme inhibition activity.Therefore, above compound can be used for hypoglycemic drug. |
| priorityDate | 2016-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.